Organic Active Ingredients TRIZ Cases

Thiadiazole compounds inhibit IRAK4 to reduce pro-inflammatory cytokines, addressing limited treatment options for inflammatory and fibrotic disorders.

Tricyclic heterocyclic compounds bind TEAD proteins to disrupt YAP-TEAD interactions.

Second-generation RAF inhibitors target mutated BRAF polypeptides to overcome treatment resistance.

Administering resiniferatoxin intrathecally targets TrpV1 receptors to improve motor functions in Parkinson's disease patients.

Combines hyaluronic acid with botulinum toxin to provide internal physical support for injured soft tissue.

Cross-linked hydrolysed starch microspheres couple endogenous charged ligands via carboxylic ester bonds to enhance biodegradability and cell attachment.

Thin film evaporation anneals co-precipitated pharmaceutical materials above their wetted glass transition temperature to increase bulk density and flowability.

A coenzyme Q10 slow-release drug uses a degradable gel isolation layer to control active ingredient release.

Formula I and II compounds bind importin7 to block ERK1/2 nuclear entry, reducing cancer cell viability.

Substituted Michael acceptors replace toxic hydroquinone with safe compounds that inhibit tyrosinase to lighten skin without inflammatory side effects.

A morpholine substituent on the triazine ring enables selective mTOR inhibition, resolving the trade-off between enzyme specificity and therapeutic efficacy.

Combining osimertinib with selpercatinib treats EGFR and RET associated cancers simultaneously.

A sprayable oily liquid formulation delivers liposoluble vitamin D3 using medium chain triglycerides and caprylic acid triglycerides.

Polyunsaturated fatty acid salts provide high binding parameters at low compression forces, reducing machine wear and capping risks.

A sodium alginate slurry with mineral oxides enhances active ingredient absorption during radio-frequency therapy.

siRNA targets protein S to rebalance coagulation, reducing infusion frequency and venous damage risks.

A transdermal drug administration device uses a matrix layer with varying water-absorbing polymer concentrations to control release rates.

Formula I compounds target the TGT enzyme to treat autoimmune diseases by normalizing cytokines and reducing inflammation.

Creatine supplementation combined with breathing exercises increases muscle and brain creatine levels to support recovery.

Formula I amide compounds selectively inhibit microglial activation pathways to reduce inflammatory responses.

Cholecalciferol sulfate magnesium and calcium salts maintain the native sulfated form in systemic fluids, preventing rapid metabolization of vitamin D3.

Amino acid salts of omega-3 fatty acids combine with anthocyanins to improve solubilization and endothelial function despite low digestive fluid secretion.

KDM5A inhibition restores antigen presentation machinery, resolving immune evasion and boosting anti-tumor responses.

Metformin reduces CRS severity by down-regulating IL-6Rα expression and preventing C-reactive protein release during immunotherapy.

A lophenol-based compound inhibits visceral fat accumulation without affecting body weight.

N-acetylglucosamine enhances N-glycan branching to inhibit PDGF receptor-alpha endocytosis, resolving incomplete remyelination in demyelinating diseases.

Dual-targeting NNMT inhibitors merge SAM and NA binding pockets to overcome poor cell permeability in cancer treatment.

Ultrasonic mesh membrane directs aerosol deep into the oral cavity, bypassing tongue obstruction to ensure accurate dosage.

Miliusane compounds inhibit viral entry and replication, addressing resistance in HIV and influenza treatments.

siRNA targeting GST-π reduces tumor size while avoiding autophagy induced by existing suppression methods.

Replacing complex imaging with CA27.29 biomarker assays to resolve contradictions between measurement precision and equipment complexity.

Antibody-based detection replaces complex chromatography to measure S-adenosylmethionine concentration without expensive equipment.

Bifunctional compounds act as muscarinic antagonists and beta2 agonists to deliver dual bronchodilation mechanisms.

Combining targeted agents with monoclonal antibodies treats non-Hodgkin lymphoma while minimizing severe toxicities associated with standard chemotherapy.

Position-specific substituents on the pyrazolo[1,5-a]pyrimidine core optimize binding affinity and selectivity for target kinases like CHK1 and CDK2.

N-acylated hyaluronic acid addresses side effects of conventional gout treatments by inhibiting xanthine oxidase and modulating cytokine production.

Liquid spray formulations with permeation enhancers bypass hepatic first-pass metabolism to improve bioavailability.

Targeting SSTR2 and MOR with specific antagonists addresses limited treatment options and high mortality in pancreatic ductal adenocarcinoma.

Indazole derivatives antagonize glucagon receptors, reducing hepatic glucose output and improving glycemic control in Type II diabetes.

Toluene-based synthesis precipitates stable apremilast polymorphs, removing complex solvent replacement and aqueous workup procedures.

Antilipemic agents modulate fatty acid transport protein 4 expression to enhance cis-retinal synthesis and preserve photoreceptor function.

A diagnostic method identifies single nucleotide polymorphisms in chromosome 2 to predict treatment responses for neuropsychiatric disorders.

Dual inhibition of ALK and JAK2 kinases by Formula I imidazopyridines overcomes resistance in proliferative disease treatment.

Targeting plasma membrane KRS reduces immune infiltration for treating fibrosis and pulmonary hypertension.

Cysteamine crosslinks polyamino acid zwitterionic polymers to create nanoparticles that release anticancer drugs in high glutathione tumor environments.

Bifunctional compounds merge miotic action with lens softening to overcome presbyopia treatment limitations without surgical complications.

Formula I compounds inhibit DPAGT1 enzyme activity, reducing cytotoxicity while treating breast cancer.

A site-specific antibody-drug conjugate delivers cytotoxic MMAE to CLDN18.2-overexpressing cells via a stable linker.

Dendritic polymer shells envelop transition metal complexes in bio-nano power cells to enable biocompatible electron transfer.

Amy22 compounds inhibit Myc/Max dimerization to shrink tumors while avoiding side effects from poor pharmacokinetics.